No Priors Ep. 121 | With Chai Discovery Co-Founders Jack Dent and Joshua Meier

AI has already fueled breakthroughs in biotechnology—but now, further advances in AI are poised to fuel pharmaceutical discoveries as well. Sarah Guo sits down with Joshua Meier and Jack Dent, co-founders of Chai Discovery, whose newly launched Chai-2 designs bespoke antibodies that bind to their targets at a jaw-dropping 20% rate. Jack and Joshua talk about the implications for Chai-2’s success rate at discovering antibodies for the pharmaceutical industry, how structure prediction is pivotal in making the model work, and future potential for using the model to optimize other molecular properties. Plus, they talk about what they believe bioscientists should be learning to best utilize Chai-2’s technology. Sign up for new podcasts every week. Email feedback to show@no-priors.com Follow us on Twitter: @NoPriorsPod | @Saranormous | @EladGil | @_jackdent | @joshim5 Chapters: 00:00 – Joshua Meier and Jack Dent Introduction 01:09 – Genesis of Chai Discovery 06:12 – Chai-2 Model 10:13 – Criteria for Specifying Targets for Chai-2 13:12 – How the Chai-2 Model Works 16:12 – Emergent Vocabulary from Chai-2 18:15 – Hopes for Chai-2’s Impact 20:33 – Reception of the Chai-2 Model 22:16 – Future of Wet Lab Screening and Biotech 27:08 – Optimizing Other Molecule Properties 31:37 – Where Chai Invests From Here 36:20 – What Bioscientists Should Learn for Chai-2 40:23 – How Jack and Josh Oriented to the Biotech Space 43:38 – Platform Investment and Chai-2 46:53 – Scaling Chai Discovery 48:21 – Hiring at Chai Discovery 49:09 – Conclusion

Sarah GuohostJoshua MeierguestJack Dentguest

Jul 2, 202549mWatch on YouTube ↗

WHAT IT’S REALLY ABOUT

AI-designed antibodies promise biotech revolution with CHAI 2.0 breakthrough

The episode features CHAI Discovery co-founders Josh Meier and Jack Dent discussing CHAI 2.0, a zero-shot generative platform that designs therapeutic antibodies with roughly 20% hit rates, a ~100x improvement over prior computational methods.
They explain how advances in protein structure prediction and generative modeling enable ‘Midjourney for molecules,’ allowing models to place atoms in 3D space with near-atomic accuracy to design binders for specified targets.
Beyond faster, cheaper discovery, they argue the real impact is unlocking previously intractable targets and entirely new molecular formats, shifting biology from an empirical science toward an engineering discipline with CAD-like tooling.
They outline CHAI’s strategy to productize the platform, open it to partners, and build interfaces that turn antibody engineers into expert prompt engineers, while scaling a small, highly interdisciplinary, engineering-centric team.

IDEAS WORTH REMEMBERING

5 ideas

Zero-shot generative models can radically compress antibody discovery.

CHAI 2.0 achieves ~20% success rates (hits in about 1 in 5 designs) with as few as 20 computationally designed antibodies per target, versus ~0.1% or lower for prior computational work and millions–billions of variants in traditional wet-lab screening.

Broad, realistic benchmarking is crucial to proving generalization in drug design models.

Instead of a few hand-picked targets, CHAI tested over 50 held-out targets scraped from vendor catalogs with low sequence similarity to training data, demonstrating that the model generalizes across diverse, unseen problems rather than overfitting one showcase case.

Structure prediction is the ‘ImageNet moment’; design is ‘Midjourney for molecules.’

High-accuracy structure prediction provides an atomic-level ‘microscope’ from sequence to 3D structure, while design models invert the problem by generatively placing complementary atoms to fit a given target—akin to going from classification to generative image models.

The real value is not just faster discovery, but new classes of targets and molecules.

Because AI models fail differently than traditional lab methods, they can succeed on previously intractable targets (e.g., hard-to-hit epitopes, cross-species binders, multi-target formats), expanding the reachable search space rather than only optimizing existing workflows.

Biotech is likely to see a CAD-like software stack for biology.

CHAI envisions a future where scientists specify complex design intents—multiple species, on/off-target profiles, manufacturability, stability—through rich prompts and software interfaces, with the model proposing candidate molecules much like SolidWorks or Photoshop aid engineers and designers.

WORDS WORTH SAVING

5 quotes

Once you start to grasp the implications that we are going to have the ability as a human race to engineer molecules with atomic precision, it’s almost hard to work on anything else with your life.

— Jack Dent

Structure prediction basically gives you an atomic-level microscope… once you can do that, the next question is: can we start moving those atoms around?

— Josh Meier

We’ve gone from a less than 0.1% success rate to a close to 20% success rate in a year. Who’s to say that in another year it can’t be 50% or even close to 100%?

— Jack Dent

It’s a good time to be a sick mouse.

— Josh Meier

We sort of enter this era where you have a computer-aided design suite for molecules in a way that we have SolidWorks for mechanical engineering or Photoshop for creatives.

— Jack Dent

Origins of CHAI Discovery and timing the AI-for-drug-discovery inflection pointCHAI 2.0’s technical breakthrough in zero-shot antibody design and benchmarkingHow structure prediction and 3D generative models enable molecular ‘lock-and-key’ designImpact on biotech economics, target space, and the broader ‘bullish on biotech’ thesisFuture product vision: CAD-like software, multi-property/multi-target optimization, and workflowsCultural and engineering practices for building a deep-tech bio+AI startupImplications for antibody engineers, biologists, and the emerging role of prompt engineering

High quality AI-generated summary created from speaker-labeled transcript.

Get more out of YouTube videos.

High quality summaries for YouTube videos. Accurate transcripts to search & find moments. Powered by ChatGPT & Claude AI.